×
About 21,125 results

ALLMedicine™ Chronic Lymphocytic Leukemia Center

Research & Reviews  5,786 results

Frequency and utility of bone marrow examination in relapsed/ refractory immune thrombo...
https://doi.org/10.1111/jth.15802
Journal of Thrombosis and Haemostasis : JTH; Taparia K, Wall E et. al.

Jun 26th, 2022 - The diagnosis of immune thrombocytopenia (ITP) is one of exclusion. While guidelines recommend against routine bone marrow examination (BME) at time of ITP diagnosis, the role of BME in relapsed/refractory ITP is unclear. To examine the frequency ...

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic l...
https://doi.org/10.1038/s41375-022-01629-7 10.2217/fon-2017-0442 10.1182/asheducation-2013.1.138 10.1038/s41375-018-0313-8 10.1182/blood-2017-09-806398 10.1056/NEJMoa1509388 10.1182/blood-2014-10-606038 10.1056/NEJMoa1815281 10.1056/NEJMoa1713976 10.1016/S1470-2045(18)30788-5
Leukemia von Tresckow J, Cramer P et. al.

Jun 26th, 2022 - Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.|2022|von Tresckow J,Cramer P,Robrecht S,Langerbeins P,Fink AM,|

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell T...
https://clinicaltrials.gov/ct2/show/NCT01087294

Jun 24th, 2022 - Background: Many patients with advanced B-cell malignancies that cannot be cured by chemotherapy and monoclonal antibodies have prolonged relapse-free survival after allogeneic hematopoietic stem cell transplantation (alloHSCT); however, a substan...

Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
https://clinicaltrials.gov/ct2/show/NCT01139476

Jun 24th, 2022 - We propose to conduct a molecular epidemiology study with a subset of participants in the Agricultural Health Study (AHS), a prospective cohort of 57,310 licensed pesticide applicators in Iowa and North Carolina. Blood and urine samples will be co...

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04739813

Jun 24th, 2022 - Background: Combination chemotherapy with rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas. Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas an...

see more →

Guidelines  9 results

TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-voluntary-withdrawal-blasnda-u2-treat
TG Therapeutics

Apr 15th, 2022 - NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Company has voluntarily withdrawn the pending Biologics License Application (BLA)/supplemental New Drug Application (sNDA) for the combinat...

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical ...
https://doi.org/10.6004/jnccn.2020.0006
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Feb 6th, 2020 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in...

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940638
Leukemia Malcikova J, Tausch E et. al.

Feb 23rd, 2018 - In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. On these grounds...

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Vers...
https://doi.org/10.6004/jnccn.2017.0030
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Zelenetz AD et. al.

Mar 10th, 2017 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmu...

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841457
Journal of the National Comprehensive Cancer Network : JN... Zelenetz AD, Gordon LI et. al.

Mar 5th, 2015 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the develop...

see more →

Drugs  47 results see all →

Clinicaltrials.gov  906 results

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
https://clinicaltrials.gov/ct2/show/NCT04030195

Jun 24th, 2022 - This is a multicenter, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate safety, tolerability, clinical activity, and find an appropriate dose to optimize safety and efficacy of PBCA...

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03204188

Jun 24th, 2022 - Background: This study investigates the combination of ibrutinib, fludarabine and pembrolizumab for treatment of CLL. Chronic lymphocytic leukemia and small lymphocytic lymphoma (hereby referred as CLL) are tumors of B cells. A subset of patients ...

Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leu...
https://clinicaltrials.gov/ct2/show/NCT04269902

Jun 24th, 2022 - PRIMARY OBJECTIVE: I. To evaluate whether early treatment with venetoclax and obinutuzumab (V-O) extends overall survival (OS) compared with delayed treatment with V-O in high-risk (Chronic Lymphocytic Leukemia [CLL] International Prognostic Indic...

CHIP/CCUS Natural History Protocol
https://clinicaltrials.gov/ct2/show/NCT04102423

Jun 24th, 2022 - Clonal Hematopoiesis of Indeterminate Potential (CHIP) has been defined as the presence of a somatic pathogenic variant associated with hematological malignancy, with an allele fraction of at least 2%, without morphological evidence of bone marrow...

Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
https://clinicaltrials.gov/ct2/show/NCT01139476

Jun 24th, 2022 - We propose to conduct a molecular epidemiology study with a subset of participants in the Agricultural Health Study (AHS), a prospective cohort of 57,310 licensed pesticide applicators in Iowa and North Carolina. Blood and urine samples will be co...

see more →

News  1,691 results

Venetoclax Combos Improve Progression-Free Survival in CLL
https://www.medscape.com/viewarticle/975652

Jun 15th, 2022 - Use of the targeted therapy combination of venetoclax plus obinutuzumab for fit patients with chronic lymphocytic leukemia (CLL) significantly improved progression-free survival (PFS) at 3 years compared with standard chemoimmunotherapy, new phase...

FDA Withdraws Lymphoma Drug Approval After Investigation
https://www.medscape.com/viewarticle/974875

Jun 1st, 2022 - Today, the US Food and Drug Administration (FDA) announced it has withdrawn approval of the lymphoma drug umbralisib (Ukoniq) following an investigation into a "possible increased risk of death." Umbralisib had received accelerated approval in Feb...

Phase-3 study: Leukemia patients live longer with ibrutinib
https://www.mdedge.com/hematology-oncology/article/254888/cll/phase-3-study-leukemia-patients-live-longer-ibrutinib
Heidi Splete

May 24th, 2022 - Chronic lymphocytic leukemia (CLL) patients aged 65 years and older who were treated with ibrutinib showed sustained progression-free and overall survival benefits up to 8 years later, based on follow-up data from the RESONATE-2 trial. “This trial.

Studies Address Ibrutinib Bleeding Risk in Patients With CLL Receiving Mohs Surgery
https://www.medscape.com/viewarticle/974234

May 18th, 2022 - Patients receiving treatment with ibrutinib for chronic lymphocytic leukemia (CLL) show significant increases in the risk for bleeding when undergoing Mohs micrographic surgery for skin cancer, indicating the need for temporary treatment interrupt...

'Agony of Choice' for Clinicians Treating Leukemia
https://www.medscape.com/viewarticle/973800

May 11th, 2022 - With an abundance of targeted therapies transforming the treatment landscape for chronic lymphocytic leukemia (CLL), picking the optimal drug or drug sequence for the right situation can be a challenge, but emerging data is helping guide clinician...

see more →

Patient Education  11 results see all →